Dow Traumatic Brain Injury and Psychological Health, Clinical Trial Award

Summary: The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines.

Distinctive Features: Funding from this award mechanism must support a clinical trial.

· Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.

· Preliminary data are required.

· The inclusion of community-based participatory research (CBPR) approaches is required.

· The CTA offers funding for two Research Levels. The applicant is responsible for selecting the Research Level based on the scope of the research.

○ Research Level 1: Supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials.

○ Research Level 2: Supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.

· Early-Career Investigator Partnering Option (available for both Research Levels): This option accommodates two Principal Investigators (PIs), one of which is an Early-Career Investigator. If recommended for funding, each PI will receive a separate award.